Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects millions of people worldwide. RA causes joint inflammation, leading to stiffness, pain, and sometimes joint deformity. Current treatments offered by the U.S. medical community for RA are often focused on managing symptoms and reducing inflammation, but they do not provide a cure.
Stem cell therapy is a promising approach for treating RA, as it aims to not only reduce inflammation but also regenerate damaged tissue in the affected joints. We believe the most effective source of stem cells for RA treatment is Wharton’s jelly-derived stem cells (WJ-MSCs).
Wharton’s jelly is a gelatinous substance found around the umbilical cord, containing a high concentration of stem cells. These cells can differentiate into various cell types, including bone, cartilage, and muscle cells, making them an extremely valuable resource for treating RA.
Studies have shown that WJ-MSCs have anti-inflammatory and immunomodulatory properties, which are crucial for treating RA. These cells can suppress the activity of immune cells that attack the joints in RA, reducing inflammation and preventing further damage.
In addition to their immunomodulatory properties, WJ-MSCs also can regenerate damaged tissue in the joints. Studies have shown that these cells can differentiate into chondrocytes, which are the cells that make up cartilage.
Cartilage damage is a common occurrence in RA, and the ability of stem cell therapy utilizing Wharton’s Jelly-derived cells to regenerate cartilage makes them a superior candidate for treating this condition.
Are There Studies That Prove the Efficacy of Stem Cell Therapy for Rheumatoid Arthritis?
Several studies have investigated the use of WJ-MSCs for RA treatment, and the results have been impressive. One study published in Stem Cells International in 2018 found that injecting WJ-MSCs into the joints infected with RA reduced inflammation and improved joint function. The study also found that the WJ-MSCs promoted the regeneration of damaged tissue in the joints.
Another study published in Stem Cells Translational Medicine in 2016 investigated the use of WJ-MSCs in combination with traditional RA medications, such as methotrexate. The study found that the combination therapy was more effective at reducing inflammation and preventing joint damage than methotrexate alone.
One potential challenge for RA patients is the limited availability of WJ-MSCs, as they can only be obtained from umbilical cords at birth. At our treatment facilities across the globe, we have established relationships that enable us to experience donations sufficient to treat our patients. Our standards are high. We do not accept donated tissue from single mothers. Our staff geneticist performs background checks on both parents to ensure there is no adverse family history. We perform DNA testing on all tissues used in our treatments and experience excellent patient outcomes.
One of the benefits of Wharton’s Jelly-derived stem cells is that no child is harmed, no mother is harmed, and both are healthy. The prescreening process that we adhere to is higher than that of the FDA or International standard.
WJ-MSCs have not yet developed an immune system, meaning there is no chance of rejection. This is not the case with stem cells derived from other tissue.
Wharton’s jelly-derived stem cells offer an optimum approach for treating rheumatoid arthritis. These cells have anti-inflammatory and immunomodulatory properties and have helped countless patients with Rheumatoid arthritis experience a better quality of life without medication.